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Introduction {#sec1}
============

As the incidence of coronavirus disease 2019 (COVID-19) has increased \[[@bib1],[@bib2]\], so has the clinical understanding of the disease. However, data on clinical presentation, complications, management and outcome are mainly obtained from relatively small case series \[[@bib1],[@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]\], mainly collected from China \[[@bib1],[@bib3], [@bib4], [@bib5],[@bib8],[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17]\] or including selected groups of critically ill patients \[[@bib6],[@bib7],[@bib18], [@bib19], [@bib20]\]. Consequently, they do not necessarily represent the current situation in European hospitals.

The main objective of this study was to describe clinical characteristics, management and outcome of individuals with COVID-19 who were admitted to our hospital in Genoa, northern Italy. We also sought to investigate risk factors associated with all-cause in-hospital mortality.

Materials and methods {#sec2}
=====================

With the first reported COVID-19 case in Genoa occurring on 25 February 2020, we created a collaborative study group (GECOVID-19) with the aim of improving the care of COVID-19 patients and conducting research at our hospital. This group prospectively recorded all consecutive patients with COVID-19 admitted to our hospital and collected data according to a pre-established clinical form.

Study design {#sec2.1}
------------

For the purpose of this study, we established a retrospective cohort including all adults hospitalized with COVID-19 during the period from 25 February to 25 March 2020. The present report was designed after data collection, but the analysis was planned before starting the data analysis.

Setting {#sec2.2}
-------

This study was conducted in a 1200-bed university-affiliated hospital (San Martino Policlinico Hospital) in Genoa, northern Italy, attending a population of approximately 400 000. During the study period, individuals with COVID-19 were admitted to the hospital if they presented Pa[o]{.smallcaps} ~2~ \<60 mmHg at rest in ambient air or if the exacerbation of their underlying diseases or severe symptoms were considered unmanageable at home.

Data collection and definitions {#sec2.3}
-------------------------------

Detailed information regarding data collection and definitions used in this study are reported in the Supplementary material ([Appendix S1](#appsec1){ref-type="sec"}). Briefly, the following data were collected from the patients\' medical records at the time of COVID-19 diagnosis (i.e. at the time of the first clinical sample recorded as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and before any antiviral or antibiotic treatment): demographics, underlying diseases, and clinical, laboratory and radiological findings. Data on treatments, COVID-19-related complications and outcome were also collected during the course of the disease.

A confirmed case of COVID-19 was defined by a positive result of an RT-PCR assay of a respiratory sample. Cardiovascular disease was defined as a history of coronary artery disease, congestive heart failure, or severe valvular heart disease with or without valve replacement. Non-invasive respiratory support techniques included high-flow nasal cannula, continuous positive airway pressure and non-invasive positive-pressure ventilation.

Data regarding the number of patients who had died, had been discharged and were still hospitalized were recorded as of 19 April 2020. The primary outcome measure was all-cause in-hospital mortality.

Microbiology {#sec2.4}
------------

Respiratory samples were tested for SARS-CoV-2 using RT-PCR targeted at open reading frame 1ab and nucleocapsid protein genes. A cycle threshold (Ct) value \< 37 defined a positive test whereas a Ct value ≥ 40 defined a negative result. Possible co-infection with respiratory viruses was ruled out by means of multiplex RT-PCR on the same respiratory sample (Allplex TM Respiratory Panel Assay, Seoul, South Korea). Bacterial and/or fungal cultures were collected according to physicians\' judgement, and microorganisms were identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and were tested for antimicrobial susceptibility with a Vitek 2 automated system (bioMérieux, Marcy l'Étoile, France).

Statistical analysis {#sec2.5}
--------------------

No statistical sample size calculation was performed. Data were retrieved from an online database for anonymous and automatic data collection \[[@bib21]\].

Quantitative variables were expressed as median and interquartile range (IQR), and qualitative variables as number and percentage. Qualitative variables were compared using the χ^2^ and Fisher\'s exact tests, as appropriate. Quantitative variables were compared by Wilcoxon rank sum test. Missing data for each variable were excluded from the denominator. Univariable analysis was used to identify potential predictors of all-cause in-hospital mortality. Potential significant baseline predictors (i.e. variables collected at the time of the first clinical sample positive for SARS-CoV-2 RNA) on univariable comparisons (p \< 0.10) were considered for the multivariable logistic regression model. A stepwise backward selection approach was used to select the predictors to include in the final multivariable model. For easier graphical interpretation, age was grouped as follows: 31--40 years, 41--50 years, 51--60 years, 61--70 years, 71--80 years and \>80 years. The analyses were performed using SPSS Statistics version 21.0 (IBM Corp., Armonk, NY, USA).

Ethical consideration {#sec2.6}
---------------------

The study protocol was approved by the Ethics Committee of Liguria Region (N.CER Liguria 114/2020-ID10420) and the need for written informed consent was waived because of the retrospective nature of the study.

Results {#sec3}
=======

Overall, 317 COVID-19 patients were included in the study. The number of hospital admissions varied substantially according to the age group, with the highest number observed among patients aged \>60 years ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Number of admissions to hospital according to age group.Fig. 1

The median age was 71 years (IQR 60--82 years) and 213/317 (67.2%) were male. Overall, 65.3% (110/317) of patients had at least one underlying disease ([Table 1](#tbl1){ref-type="table"} ). Hypertension was the most frequent underlying disease (149/317; 47.0%), followed by cardiovascular disease (63/317; 19.9%), diabetes mellitus (49/317; 15.5%) and neurological disease (28/317; 8.8%).Table 1Clinical characteristics of the 317 hospitalized patients at the time of COVID-19 diagnosisTable 1Characteristics[a](#tbl1fna){ref-type="table-fn"}Patients (*n* = 317Age, years71 (60--82)Sex, male213 (67.2)Underlying disease Hypertension149 (47.0) Cardiovascular disease63 (19.9) Diabetes mellitus49 (15.5) Neurological disease28 (8.8) Chronic kidney disease22 (6.9) Chronic obstructive lung disease18 (5.7) Solid cancer12 (3.8) Haematological malignancy11 (3.5)Number of underlying diseases 0110 (34.7) 195 (30.0) 262 (19.6) ≥350 (15.8)Charlson co-morbidity index4 (2-5)Time from illness onset to hospital admission, days5 (2-8)Signs and symptoms Fever (Temperature \>37.3°C)285 (89.9) Shortness of breath167 (52.7) Dry cough156 (49.2) Asthenia57 (18.0) Mental confusion29 (9.1) Diarrhoea18 (5.7) Myalgia18 (5.7) Headache14 (4.4) Nausea and vomiting14 (4.4) Sputum9 (2.8)Physical examination Tachypnoea140 (44.2) Tachycardia89 (28.1) Hypotension3 (0.9)Laboratory findings Lymphopenia192/281 (68.3) Thrombocytopenia114/272 (41.9) ALT \>40 U/L105/303 (34.7) AST \>40 U/L102/300 (32.2) Hypokalaemia78/302 (25.8) Leukopenia53/303 (17.4)Inflammatory markers[b](#tbl1fnb){ref-type="table-fn"} C-reactive protein, mg/L (*n* = 301)79.3 (33.7-132.5), D-dimer, μg/L (*n* = 278)1050 (630.7-1565.7) Interleukin-6, ng/L (*n* = 252)46.7 (20.0-97.9)Hypoxaemic respiratory failure199/310 (64.2)Acute kidney injury56/303 (18.5)Radiological findings Pulmonary consolidation200/294 (68.0) Bilateral124/200 (62.0) Monolateral76/200 (38.0) Interstitial pattern124/294 (42.2) Absence of lesions35/294 (11.9) Pleural effusion11/294 (3.7)[^3][^4][^5]

The median duration of symptoms before diagnosis was 5 days (IQR 2--8 days). At the time of COVID-19 diagnosis, the most common symptoms included fever (285/317; 89.9%), shortness of breath (167/317; 52.7%) and dry cough (156/317; 49.2%). Overall, 16.7% of the patients (53/317) presented with atypical clinical manifestations consisting of mental confusion, diarrhoea and nausea or vomiting in 9.1% (29/317), 5.7% (18/317) and 4.4% (14/317), respectively (3 out of 317 patients (0.9%) presented with only atypical manifestations at the time of COVID-19 diagnosis).

Lymphopenia was the most common haematological abnormality (198/281; 68.3%) followed by thrombocytopenia (114/272; 41.9%) and elevated serum transaminase levels. Hypokalaemia was also a common finding, observed in 25.8% of the patients (78/302) at the time of diagnosis, as was acute kidney injury (AKI) (56/303; 18.5%).

Of the 294/317 (92.7%) chest radiographs that were performed, 259/294 (88.1%) revealed abnormal results. The most common pattern was pulmonary consolidations in 200/294 (68.0%) patients, of which 124/200 (62.0%) were bilateral. One hundred and twenty-four patients out of 294 had an interstitial pattern (42.2%).

Of the patients with laboratory-confirmed COVID-19, nearly three-quarters (217/317; 68.5%) had urine sent to test for *Streptococcus pneumoniae* and *Legionella pneumophila* antigens but all were negative. Eighty-two of the 317 patients (25.8%) had blood cultures performed at the time of COVID-19 diagnosis, but there was no evidence of bacterial co-infection in any patients. Moreover, none of the 34 respiratory tract samples (7 sputum and 27 bronchoalveolar lavage fluid) tested for bacterial, viral or fungal pathogens at the time of diagnosis was positive.

As for treatment, most patients received hydroxychloroquine (225/317; 71.0%) and a combination treatment with darunavir/ritonavir (155/317; 48.9%) or oseltamivir (32/317; 10.1%). One-hundred and twenty-two individuals out of 317 (38.5%) were treated with methylprednisolone and 61/317 (19.2%) received tocilizumab ([Table 2](#tbl2){ref-type="table"} ). Two-hundred and three patients out of 317 (64.0%) were treated with intravenous antimicrobials, most commonly a fifth-generation cephalosporin or a third-generation cephalosporin with either a macrolide or a fluoroquinolone.Table 2Treatments and outcomes of hospitalized patients with COVID-19Table 2Characteristics[a](#tbl2fna){ref-type="table-fn"}Patients (*n* = 317Anti-infectious drugs Hydroxychloroquine225 (71.0) Darunavir/ritonavir155 (48.9) Oseltamivir32 (10.1) Lopinavir-ritonavir4 (1.3) Remdesivir2 (0.6)Anti-inflammatory drugs Corticosteroids122 (38.5) Tocilizumab61 (19.2)Antibiotics[b](#tbl2fnb){ref-type="table-fn"} Fifth-generation cephalosporin123 (38.8) Third-generation cephalosporin46 (14.5) Macrolides26 (8.2) β-lactams/β-lactamase inhibitor24 (7.6) Fluoroquinolones9 (2.8) Others7 (2.2)Complications during the hospitalization ARDS development116 (36.6) Non-invasive respiratory support111 (35.0) ICU admission65 (20.5) Invasive mechanical ventilation60 (18.9) Septic shock15 (4.7) CRRT9 (2.8)ICU length of stay, days (*n* = 46)12.0 (6.5--21.5)Hospital length of stay, days, (*n* = 275)12.0 (5.0--19.0)All-cause in hospital mortality120/275 (43.6)[^6][^7][^8]

The majority of patients received oxygen therapy and 111 out of 317 (35.0%) required non-invasive respiratory support. Among them, 47.8% (53/111) subsequently required invasive mechanical ventilation ([Table 2](#tbl2){ref-type="table"}).

Overall, 20.5% (65/317) of patients needed intensive care and 18.9% (60/317) underwent invasive mechanical ventilation for a median of 9 days (IQR 4.5--16.5 days). None received extracorporeal membrane oxygenation. During hospitalization, 9/317 (2.8%) patients developed AKI requiring continuous renal replacement therapy.

On 19 April 2020, a total of 275 (86.7%) patients were no longer hospitalized: 120/275 (43.6%) had died in the hospital and 155/275 (56.4%) had been discharged alive. Comparison between survivors and non-survivors is shown in [Table 3](#tbl3){ref-type="table"} . On multivariable analysis, only age (per-year increase odds ratio OR 1.07; 95% CI 1.04--1.10; p \< 0.001), cardiovascular disease (OR 2.58; 95% CI 1.07--6.25; p 0.03), and C-reactive protein (CRP) levels (per-point increase OR 1.009; 95% CI 1.004--1.014; p 0.001) retained an independent association with all-cause in-hospital mortality ([Table 4](#tbl4){ref-type="table"} ). An additional multivariate model excluding CRP and IL-6 (i.e. those variables with the highest number of missing values) suggested that AKI at the time of COVID-19 diagnosis was a possible additional, independent predictor of increased in-hospital mortality (OR 3.31; 95% CI 1.53--7.16; p 0.002; complete model results are available in the Supplementary material, [Table S1](#appsec1){ref-type="sec"}). Survival curves according to age groups for the entire study population and for those patients with no previous underlying disease are shown in [Fig. 2](#fig2){ref-type="fig"} and see Supplementary material, [Fig. S1](#appsec1){ref-type="sec"}, respectively.Table 3Comparison of baseline clinical characteristics and laboratory findings of patients who had been discharged (*n* = 155) or had died (*n* = 120) as of 19 April 2020Table 3Characteristics[a](#tbl3fna){ref-type="table-fn"}In-hospital survivors (*n* = 155)In-hospital non-survivors (*n* = 120)pAge, years65 (52--76)81 (72--87)\<0.001Sex, male98 (63.2)85 (70.8)0.20Underlying disease Hypertension57 (36.8)75 (62.5)\<0.001 Diabetes mellitus16 (10.3)26 (21.7)0.01 Cardiovascular disease16 (10.3)39 (32.5)\<0.001 Chronic kidney disease5 (3.2)14 (11.7)0.01 Neurological disease6 (3.9)20 (16.7)\<0.001 Chronic obstructive lung disease4 (2.6)11 (9.2)0.03 Solid cancer3 (1.9)7 (5.8)0.11 Haematological malignancy3 (1.9)6 (5.0)0.19Number of underlying diseases 080 (51.6)18 (15.0)\<0.001 144 (28.4)34 (28.3)1 220 (12.9)31 (25.8)0.08 ≥311 (7.1)37 (30.8)\<0.001Charlson co-morbidity index2.0 (1.0--4.0)5.0 (4.0--6.0)\<0.001Time from illness onset to diagnosis, days6.0 (3.0--8.0)3.0 (2.0--7.0)0.001Signs and symptoms Fever (temperature \>37.3°C)146 (94.2)104 (86.7)0.04 Dry cough86 (55.5)50 (41.7)0.03 Shortness of breath67 (43.2)79 (65.8)\<0.001 Asthenia34 (21.9)16 (13.3)0.08 Myalgia15 (9.7)3 (2.5)0.03 Headache12 (7.7)2 (1.7)0.03 Diarrhoea8 (5.2)6 (5.0)1.00 Nausea and vomiting8 (5.2)3 (2.5)0.36 Sputum7 (4.5)1 (0.8)0.14 Mental confusion3 (1.9)22 (18.3)\<0.001Physical examination Tachypnoea55 (32.9)71 (59.2)0.01 Tachycardia36 (23.2)37 (30.8)0.14 Hypotension1 (0.6)2 (1.7)0.59Laboratory findings Lymphopenia84/137 (61.3)81/104 (77.9)0.008 Hypoxaemic respiratory failure72/152 (47.4)104/116 (89.7)\<0.001 ALT \>40 U/L49/145 (33.8)38/114 (33.3)1.00 AST \>40 U/L45/131 (34.4)54/103 (52.4)0.01 Leukopenia38/145 (26.2)25/116 (21.6)0.47 Hypokalaemia33/146 (22.6)56/116 (48.3)\<0.001 Thrombocytopenia23/146 (15.8)19/116 (16.4)1.00Inflammatory markers C-reactive protein, mg/L (*n* = 260)57.2 (20.0-- 111.5)109.0 (73.1--169.0)0.001 D-dimer, μg/L (*n* = 237)867.0 (480.6--1330.5)1317.0 (935.9--2284.0)0.22 Interleukin-6, ng/L (*n* = 216)27.4 (15.0--54.374.0 (43.8--142.0)0.02Acute kidney injury12/146 (8.2)38/116 (32.8)0.001Treatments Hydroxychloroquine109 (70.3)78 (65.0)0.36 Antibiotics86 (55.5)81 (67.5)0.05 Darunavir/ritonavir80 (51.6)52 (43.3)0.18 Corticosteroids54 (34.8)40 (33.3)0.90 Tocilizumab33 (21.3)17 (14.2)0.16 Oseltamivir20 (12.9)9 (7.5)0.17Complications during hospitalization Non-invasive respiratory support47 (30.3)39 (32.5)0.79 ARDS development31 (20.0)63 (52.5)\<0.001 ICU admission16 (10.3)30 (25.0)\<0.001 Invasive mechanical ventilation14 (9.0)28 (23.3)\<0.001 Septic shock2 (1.3)8 (6.7)0.02 CRRT1 (0.6)2 (1.7)0.58ICU length of stay (*n* = 46)14.0 (9.3--20.0)8.5 (4.5--17.0)0.05Hospital length of stay (*n* = 275)13.0 (6.0--19.3)10.0 (4.0--17.0)0.04[^9][^10]Table 4Multivariable analysis for risk factors associated with all-cause in-hospital mortalityTable 4CharacteristicsOR95% CIpCardiovascular disease2.581.07--6.250.03Acute kidney injury2.320.87--6.230.09Age (per-year increase)1.071.04--1.10\<0.001CRP, mg/L (per-point increase)1.0091.004--1.0140.001IL-6, ng/L (per-point increase)1.0021.000--1.0040.07[^11]Fig. 2All-cause hospital mortality of individuals with COVID-19 according to age. Median days (interquartile range) after COVID-19 diagnosis in each age group were as follows: 10.5 (1.5--17.8), 8 (2.0--18.7), 11.0 (5.0--16.0), 13.5 (5.8--19-0), 11.0 (4.5--18.5) and 8.0 (3.0--14.0) days for patients aged 31--40, 41--50, 51--60, 61--70, 71--80 and \> 80 years, respectively.Fig. 2

Discussion {#sec4}
==========

The findings of the present cohort study conducted in a teaching hospital in northern Italy can be summarized as follows: (a) COVID-19 is mainly a disease of the elderly, with multiple underlying conditions and frequent atypical presentations; (b) overall in-hospital mortality is particularly high (120/275; 43.6%) and complications are common; and (c) age, cardiovascular disease and increased CRP were associated with all-cause in-hospital mortality in our study.

In our series, we observed an uneven age distribution among hospitalized COVID-19 patients, with more than 50% being aged ≥70 years. This percentage is significantly higher than that observed in China \[[@bib1],[@bib3],[@bib4],[@bib8],[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17]\]. Indeed, the pooled mean age of patients hospitalized with COVID-19 in 14 previous Chinese studies that included unselected patients was only 50 years \[[@bib1],[@bib3],[@bib4],[@bib8],[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17]\]. Reasons for the predominance of old patients in our report are not clear, although they may be attributable to the ageing Italian population \[[@bib22]\], or the fact that, compared with young patients, older ones have an increasing risk of chronic co-morbidities that predispose them to more severe form of COVID-19 \[[@bib4],[@bib6]\].

The clinical manifestations most commonly observed in our study included fever, shortness of breath and dry cough. Fever and shortness of breath were also common findings in case series of COVID-19 patients from China and the USA \[[@bib1],[@bib3],[@bib4],[@bib8],[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17],[@bib23],[@bib24]\], and these findings have been considered as prognostic indicators for adult respiratory distress syndrome and higher mortality \[[@bib18]\]. Surprisingly, our data show that 16.7% of patients (53/317) with COVID-19 had 'atypical' clinical manifestations such as mental confusion, diarrhoea or nausea and vomiting. Although these atypical manifestations could potentially lead to a delay in diagnosis \[[@bib25]\] with possible uncontrolled transmission of the infection, it should be addressed that in our cohort there were only 3/317 patients (0.9%) who presented with only atypical manifestations. Accordingly, even in our outbreak setting, the level of COVID-19 suspicion should be low in the absence of fever, cough or shortness of breath.

With regards to laboratory findings, we observed a high proportion of patients with AKI at the time of COVID-19 diagnosis. This finding was only occasionally reported in previous series \[[@bib6],[@bib12]\]; we believe that the likely contributing factors include dehydration due to diarrhoea and poor oral feeding and side effects of symptomatic drugs (i.e. non-steroidal anti-inflammatory drugs). Whether coronavirus has a pathogenic effect on kidneys warrants further investigation \[[@bib26]\]. Contrary to what was expected, the rate of hypokalaemia in our population was also high, reaching 25.8% (78/302). This is consistent with that previously reported for the SARS-CoV outbreak in 2003 in Singapore \[[@bib27]\]. Although the mechanism of hypokalaemia is still unknown, a role of diarrhoea or vomiting might be postulated. Of note, hypokalaemia could predispose patients to develop cardiac arrhythmias, which previous authors observed in about 7%--16% of individuals with COVID-19 \[[@bib5],[@bib24]\].

In our cohort, the number of antibiotics prescribed to COVID-19 patients was particularly high, suggesting substantial inappropriate prescription of antibiotics. This finding might reflect the lack of scientific evidence on how to properly manage patients with COVID-19 in the early stages of the pandemic. Moreover, the high number of patients presenting with radiological images suggestive for pulmonary consolidation (200/294; 68.0%), could have increased the suspicion of bacterial co-infection. However, in our study, which was based on routine clinical practice, we were not able to document any bacterial co-infection. On the basis of these results, we think improving the differential diagnosis between SARS-CoV-2 and bacterial respiratory pathogens should become a critical research priority, to reduce, in line with antimicrobial stewardship principles, the rates of unnecessary antibiotic prescriptions in individuals with COVID-19.

With the exception of remdesivir \[[@bib28]\], no other specific antiviral therapy has been found to provide benefit for COVID-19 to date, and treatment mainly consists of supportive care \[[@bib5],[@bib19],[@bib29],[@bib30]\]. In the present study, 71.0% (225/317) and 48.9% (155/317) of the patients received hydroxychloroquine and darunavir/ritonavir, respectively. Although no effective outcomes were observed for hydroxychloroquine \[[@bib31]\] and protease inhibitors \[[@bib32]\] in two recent studies, future randomized studies should be performed to clarify the impact of antiviral drugs on the natural history of the disease.

Despite aggressive supportive treatment of respiratory and renal complications, we observed a striking all-cause in-hospital mortality of 43.6% (120/275), which is greater than previously reported rates from Chinese and US patients \[[@bib1],[@bib3],[@bib4],[@bib8],[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17],[@bib23],[@bib24]\]. Our main hypothesis was that the high mortality associated with COVID-19 probably reflects the old age of our patients and the severity of underlying diseases. However, increased CRP levels were also associated with death. High levels of CRP have also been associated with the severity of the disease \[[@bib18]\], possibly suggesting the involvement of cytokine storm in the clinical outcome of the patients \[[@bib18],[@bib33],[@bib34]\]. The implication of the host immune response in COVID-19 suggests a potential role of anti-inflammatory drugs as adjunctive therapy. However, the role of corticosteroids or tocilizumab---a recombinant humanized monoclonal antibody inhibiting membrane-bound and soluble interleukin-6 receptors \[[@bib35]\]---remains controversial \[[@bib29]\], even if case reports \[[@bib36],[@bib37]\] and case series \[[@bib38]\] have reported benefits. Although we cannot advocate the universal use of corticosteroids and tocilizumab in individuals with COVID-19, follow-up studies evaluating the role of anti-inflammatory drugs are warranted \[[@bib30]\]. Finally, the independent association we found between AKI and increased mortality in the additional multivariable model may reflect the unfavourable prognostic effect of organ dysfunction and/or severe disease presentation.

Our study has several limitations. First, it is a retrospective analysis and we did not examine all aspects of care that potentially could influence the outcome. For example, data are lacking about some important clinical characteristics that have been found associated with COVID-19 severity, such as weight, body mass index and smoking status. Second, this study was performed at a single institution of northern Italy and the results may not be representative of other Italian or European centres. Third, some data were missing for certain patients included in this study. Therefore, studies with the inclusion of more patients would be needed to increase the statistical power and lend support to inflammatory markers (e.g. CRP, interleukin-6) as risk of in-hospital death. Finally, among our study population, 42/317 were still hospitalized at the time of writing this report. Therefore, all-cause in-hospital mortality could be underestimated.

In conclusion, in our cohort, COVID-19 mainly affected elderly individuals with predisposing conditions and caused severe illness that frequently required non-invasive respiratory support or admission to intensive care. Despite supportive care, COVID-19 remains associated with a substantial risk of all-cause in-hospital mortality.
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[^1]: A. Vena and D.R. Giacobbe contributed equally to the study.

[^2]: The members of the GECOVID study group are listed at the [Appendix](#appsec3){ref-type="sec"} section.

[^3]: Abbreviations: ARDS, acute respiratory distress syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[^4]: Continuous values are shown as median (interquartile range); all other values are *n* (%).

[^5]: Normal C-reactive protein levels: 0.0--0.5 mg/L; normal D-dimer levels: 0.0--500.0 μg/L; normal IL-6 levels: 0.0--3.5 ng/L.

[^6]: Abbreviations: ARDS, acute distress respiratory syndrome; CRRT, continuous renal replacement therapy; ICU intensive care unit.

[^7]: Continuous values are shown as median (interquartile range); all other values are *n* (%).

[^8]: Overall, 203/317 (64.0%) received antibiotics (32 combination therapy). Others include: two oxazolidinones; one nitroimidazole and one glycopeptide.

[^9]: Abbreviations: ARDS, acute respiratory distress syndrome; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRRT, continuous renal replacement therapy; ICU, intensive care unit.

[^10]: Continuous values are shown as median (interquartile range); all other values are *n* (%).

[^11]: Overall, 211 out of 275 patients (76.3%) were included in the multivariate model because C-reactive protein (CRP) and interleukin-6 (IL-6) values were missing in 15/275 (5%) and 59/275 (21%) individuals, respectively.
